ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1485

Risk of Diabetes Mellitus in Systemic Lupus Erythematosus: Systematic Review and Meta-analysis

CLAUDIA MENDOZA PINTO1, Pamela Munguía-Realpozo1, Ivet Etchegaray-Morales2, Mario García-Carrasco2 and Socorro Méndez Martínez1, 1Instituto Mexicano del Seguro Socia, Puebla, Mexico, 2Medicine School, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico

Meeting: ACR Convergence 2023

Keywords: metabolic syndrome, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1442–1487) SLE – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that increases the risk of severe clinical outcomes and mortality. However, the association between SLE and the risk of diabetes mellitus (DM) is unclear. Our study aimed to investigate the risk of DM and to evaluate the impact of SLE therapies on the risk of developing DM in patients with SLE.

Methods: Electronic database searches of PubMed, Embase, Cochrane Library, and Web of Science, together with hand search, were performed from inception to February 2023. Studies analyzing the relationships between risk factors for DM in SLE patients in cohort or case-control were included. Data were pooled utilizing fixed- or random-effects metanalysis to estimate pooled relative risk (RR) and 95% confidence intervals (CIs). The study was registered with PROSPERO, CRD42023402774.

Results: A total of 36 studies (23 case-control and 13 cohort studies) involving 265,822 patients with SLE were included. In the pooled analysis from case-control studies, we found a greater risk (OR = 1.05, 95% CI 0.87-1.27; P = 0.63) of diabetes in patients with SLE compared with non-SLE controls. However, the pooled risk estimate of cohort studies did not show a significant risk of DM (RR= 1.32, 95% CI 0.93-1.87; P = 0.12). In a subgroup analysis, reduced risk of diabetes was reported with antimalarials (RR= 0.56, 95% CI 0.42-0.75; P < 0.001), while glucocorticoids use was associated with an increased risk of developing diabetes (RR= 1.45, 95% CI 1.20-1.76; P = 0.0002). Age, sex, hypertension, and immunosuppressants were not associated with DM in SLE patients.

Conclusion: Although there was not an increased risk of DM in overall SLE patients compared to controls, antimalarials users or adherents had a decreased risk, while GCT users had an increased risk.

Supporting image 1

Forest plot of DM risk in SLE patients treated with glucocorticoids


Disclosures: C. MENDOZA PINTO: None; P. Munguía-Realpozo: None; I. Etchegaray-Morales: None; M. García-Carrasco: None; S. Méndez Martínez: None.

To cite this abstract in AMA style:

MENDOZA PINTO C, Munguía-Realpozo P, Etchegaray-Morales I, García-Carrasco M, Méndez Martínez S. Risk of Diabetes Mellitus in Systemic Lupus Erythematosus: Systematic Review and Meta-analysis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/risk-of-diabetes-mellitus-in-systemic-lupus-erythematosus-systematic-review-and-meta-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-of-diabetes-mellitus-in-systemic-lupus-erythematosus-systematic-review-and-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology